熱門資訊> 正文
Edwards Lifesciences赞扬CMS NCD经导管主动脉瓣置换术
2026-09-11 06:33
- Edwards Lifesciences (EW) said that an updated CMS national coverage determination will ease patient access to transcatheter aortic valve replacement.
- The NCD states that CMS will now cover TAVR for symptomatic severe aortic valve stenosis (aortic stenosis) without the coverage with evidence development requirement. Also, it expands coverage of TAVR to asymptomatic severe aortic stenosis with coverage with evidence development.
- In addition, coverage criteria dealing with pre-procedural patient assessment, intraoperative requirements, and operator and hospital procedural volume requirements have been revised.
- "Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team," the company said in a news release.
- "The modernized policy recognizes the importance of timely care by supporting a more streamlined patient care journey and giving Heart Teams greater flexibility to apply their expertise to both patient evaluation and treatment based on each patient’s clinical needs."
- Edwards noted that it “has confidence” in its 2026 guidance, adding that 2027 guidance will come in December at its investor conference.
More on Edwards Lifesciences
- Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound
- Edwards Lifesciences: Strong Execution, But Little Room For Error At $90
- Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else
- Baron Asset Fund adds CBRS and EW; exits FICO and FND
- Edwards lifts 2026 sales growth outlook to 10%-11% while reaffirming $2.95-$3.05 EPS
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
